Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Carbidopa-Levodopa Treatment Report
What is Carbidopa-Levodopa?

Levodopa is a dopamine precursor used to treat the movement disorder symptoms of Parkinson's disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine.

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
5 100%

Dosages

Top 10 dosages based on patients currently taking Carbidopa-Levodopa. See all 11 dosages ►

  25mg-100mg as needed 25 mg daily 50 mg daily 25 mg-100 mg daily 25 mg-250 mg daily 2 x 25 mg-100 mg daily 250 mg daily 3 x 25 mg-100 mg daily 500 mg daily 3 x 25 mg-250 mg daily 4 x 50 mg-200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Carbidopa-Levodopa (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
2 67% Doctor's advice: 67%
Other
1 33% Other: 33%

See all 3 patients who’ve stopped taking Carbidopa-Levodopa

Duration See details about how long patients take this treatment ▼

Currently Taking Carbidopa-Levodopa

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Carbidopa-Levodopa

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
3 60%
Usually
2 40%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 20%
Not at all
4 80%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
1 20%
$25-49
2 40%
< $25
2 40%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 21, 2010.